New drug aims to stop kidney transplant rejection

NCT ID NCT05156710

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a drug called BIVV020 in 48 kidney transplant recipients. The goal is to see if it can prevent or treat antibody-mediated rejection, a common cause of transplant failure. Participants receive BIVV020 plus standard care, and researchers monitor rejection rates and kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BIVV020 (a drug given by injection to target the immune system)

What this could lead to

If successful, this could offer a new option to prevent or treat kidney transplant rejection, helping more people keep their transplanted kidney longer.

What could go wrong

This is an early-phase trial with only 48 participants, so results may not apply to everyone. The drug may not work better than current treatments, and side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSPLANT REJECTION

Contacts and locations

Show contact details

Locations

Brigham & Women's Hospital- Site Number : 8400004

Boston, Massachusetts, 02115, United States
Cedars-Sinai Medical Center- Site Number : 8400100

Los Angeles, California, 90048, United States
Investigational Site Number : 1240001

Vancouver, British Columbia, V6Z 1Y6, Canada
Investigational Site Number : 1240002

London, Ontario, N6A 5A5, Canada
Investigational Site Number : 1240003

Montreal, Quebec, H4A 3J1, Canada
Investigational Site Number : 1240101

Vancouver, British Columbia, V5Z 1M9, Canada
Investigational Site Number : 2500001

Paris, 75010, France
Investigational Site Number : 2500002

Créteil, 94010, France
Investigational Site Number : 2500005

Toulouse, 31059, France
Investigational Site Number : 2500007

Bordeaux, 33076, France
Investigational Site Number : 2760001

Munich, 81675, Germany
Investigational Site Number : 2760002

Berlin, 13353, Germany
Investigational Site Number : 2760004

Essen, 45147, Germany
Investigational Site Number : 3800001

Brescia, Lombardy, 25123, Italy
Investigational Site Number : 3800002

Rome, Lazio, 00168, Italy
Investigational Site Number : 3800003

Milan, Milano, 20162, Italy
Investigational Site Number : 3800004

Bologna, Emilia-Romagna, 40138, Italy
Investigational Site Number : 7240002

Madrid, Madrid, Comunidad de, 28046, Spain
Investigational Site Number : 7240003

Madrid, Madrid, Comunidad de, 28041, Spain
Investigational Site Number : 7240004

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number : 7520001

Huddinge, 141 57, Sweden
Investigational Site Number : 7520002

Uppsala, 751 85, Sweden
Massachusetts General Hospital- Site Number : 8400007

Boston, Massachusetts, 02114, United States
NYU Langone Medical Center- Site Number : 8400102

New York, New York, 10016, United States
University of California Los Angeles Medical Center- Site Number : 8400103

Los Angeles, California, 90095, United States
University of California San Francisco - Parnassus Heights- Site Number : 8400001

San Francisco, California, 94143, United States
University of Wisconsin Hospitals and Clinics- Site Number : 8400003

Madison, Wisconsin, 53792, United States